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Abstract Prostate cancer is the commonest solid-organ can-
cer diagnosed in males and represents an important source of
morbidity and mortality worldwide. Imaging plays a crucial
role in diagnosing prostate cancer and informs the ongoing
management of the disease at all stages. Several novel molec-
ular imaging technologies have been developed recently that
have the potential to revolutionise disease diagnosis and the
surveillance of patients living with prostate cancer. These in-
novations include hyperpolarised MRI, choline PET/CT and
PSMA PET/CT. The major utility of choline and PSMA PET/
CT currently lies in their sensitivity for detecting early
recurrence after radical treatment for prostate cancer and
identifying discrete lesions that may be amenable to
salvage therapy. Molecular imaging is likely to play a future
role in characterising genetic and biochemical signatures in
individual tumours, which may be of particular significance
as cancer therapies move into an era of precision medicine.
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Introduction
Prostate cancer is the most frequently diagnosed malignancy
in men and is the second commonest cause of male cancer-
related deaths in Europe and North America [1, 2]. Disease
that is organ-confined at the time of diagnosis is associated
with a good prognosis and is frequently amenable to curative
therapy [2, 3]. Conversely, metastatic disease heralds a poor
prognosis; men with skeletal metastases have a 5-year survival
rate below 30 % [4, 5].
Molecular imaging describes a discipline that emerged in
the early 2000s and facilitates the visualisation of biological
interactions at the cellular level [6]. Unlike traditional imaging
modalities, such as ultrasound or conventional CT, molecular
imaging techniques are able to probe the biochemical abnor-
malities that underpin a particular disease process. Clearly,
this will prove an invaluable tool for planning individualised
treatments as we progress toward an era of personalised med-
icine, whereby cancer is viewed as a genetically and biochem-
ically heterogeneous disease best managed with tailored
therapies [7–10].
This review aims to discuss molecular imaging techniques
currently employed in the assessment of prostate cancer and to
also familiarise the reader with ongoing developments that are
likely to have clinical application in the near future.
Molecular Imaging as a Diagnostic and Staging Tool
in Newly Diagnosed Prostate Cancer
Radiological imaging plays an important role in the diagnosis
and initial staging of prostate cancer. For many decades, trans-
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rectal ultrasound (TRUS)-guided biopsy has served as the
standard technique for obtaining prostatic tissue for diagnosis.
In recent years, multi-parametric MRI (MP-MRI) has
emerged as a vital tool for the diagnosis and accurate staging
of prostate cancer [11, 12]. To date, no CT- and/or PET-based
imaging modalities have demonstrated any benefit over MRI
in the imaging of early prostate cancer [13–15]. However,
advances in MR spectroscopy seem likely to permit technol-
ogies for use in clinical contexts that provide data on tumour
metabolism, thus helping to establish the aggressiveness of
discrete malignant foci.
A promising development in this area is the emergence of
hyperpolarised [1-13C] pyruvate as an adjunct to conventional
MR. Hyperpolarised MR is a novel molecular imaging tech-
nique that can be used to monitor the metabolism of endoge-
nous biomolecules [16•, 17]. Pre-clinical mouse models of
prostate cancer have described increased signal detected by
MR from hyperpolarised lactate in malignant relative to nor-
mal tissues, with levels of both hyperpolarised lactate and
pyruvate seen to increase with progression and reduce after
therapy [18, 19]. A promising study in humans demonstrates
the safety and feasibility of hyperpolarised pyruvate injections
in men with prostate cancer [16•]. This study demonstrates
that elevated levels of hyperpolarised pyruvate are observed
in regions of biopsy-proven prostate cancer. In addition to its
use as a diagnostic tool, it seems probable that refinements in
this approach will provide insights into individual tumour bi-
ology and behaviour. If this comes to fruition, hyperpolarised
MR will undoubtedly aid the risk stratification of organ-
confined malignancy at the time of diagnosis and also serve
as a powerful tool to monitor disease in patients managed on
an active surveillance protocol.
Detecting Early Recurrence After Radical Therapy
The aim of radical treatment in prostate cancer is to cure men
of their disease. Unfortunately, a proportion of men will de-
velop disease relapse despite radical therapy. Therefore, an
important aspect of the management of men who have under-
gone radical therapy involves surveillance and detection of
recurrence. A rising PSA level after radical therapy is indica-
tive of disease relapse. The management of recurrent disease
will depend on several factors, including the PSAvelocity and
extent and location of disease [20]. Advances in molecular
imaging provide new opportunities to assess the extent and
distribution of recurrent disease. Choline PET/CT is a tech-
nique that is becoming increasingly employed as a standard
imagingmodality in cases of suspected relapse.More recently,
the imaging agent Ga-68 prostate-specific membrane antigen
(Ga-68 PSMA) used in conjunction with PET/CT has been
shown to detect early recurrence with very high sensitivity
[21].
Choline PET Scanning as a Tool for Identifying
Early Recurrence
A study from 2011 evaluated 43 patients who underwent rad-
ical prostatectomy with 31 days after C11-choline PET scan
[22]. Trans-axial images and histological specimens were
analysed by comparing the respective slices. This study
demonstrated that small tumours (<5 mm) were poorly
detected while larger tumours tended to be well delineated by
PET.
The greatest utility of choline PET scanning appears to be
in the context of rising PSA following definitive local therapy.
This is of particular use in patients with biochemical relapse,
whereby PSA elevation is the only manifestation of
their disease. In this context, choline PET scanning
can help distinguish between localised, regional and dis-
tant disease recurrence. This informs disease manage-
ment as the extent of recurrence helps define treatment
options. For example, small areas of local recurrence
may be amenable to salvage radiotherapy, whereas early
detection of distant disease may facilitate the timely
introduction of anti-androgen therapy (ADT) [23]. In
one study of 63 patients with biochemical relapse, 56 % (35/
63) had abnormal choline PET scans. Recurrent disease could
be localised in 36 % of patients with PSA value <1 ng/ml,
43 % with PSA value between 1 and 2 ng/ml, 62 % with
PSAvalue between 2 and 3 ng/ml and 73 % with a PSAvalue
above 3 ng/ml [24].
An additional study of 170 patients with biochemical
failure post-radical prostatectomy demonstrated that
44 % of patients had a positive C11-choline PET scan.
Interestingly, there appears to be an association between
PSA doubling time (PSADT) and the ability of choline
PET to detect recurrence. The percentage of patients
with positive PET scans in whom the PSADT was
>6 months was just 27 %, compared to 81 % where
the PSADT was <3 months [25]. Similarly, a correlation
exists between PSA velocity (PSAV) and positive cho-
line PET scans in patients with biochemical relapse after
prostatectomy—patients with positive C11-choline PET
scans have significantly higher PSAV (p< 0.05) than pa-
tients with negative scans [26]. These data suggest a
relationship between PSA kinetics and choline uptake
in the context of biochemical relapse. In summary, cho-
line PET scanning is increasingly employed as a method
for localising recurrent tumours in patients with bio-
chemical relapse. Already, choline PET is being used
to help plan whether with recurrent disease patients
would benefit from localised or systemic therapies. A
drawback of this technique is that it only appears to be useful
once a diagnosis of biochemical relapse has been made and is
currently not able to detect recurrent disease before a rise in
PSA is noted.
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Prostate-Specific Membrane Antigen PET (PSMA
PET)—a Technique for Detecting Very Early
Recurrence
Although choline-based PET imaging is increasingly used for
the detection of recurrent disease following curative therapy,
several studies have reported concerns regarding sensitivity
and specificity at low PSA levels [27–29]. Consequently,
there is a need for a reliable diagnostic test in patients
presenting with early biochemical failure. With this in
mind, radionuclide imaging agents that target the cell
surface receptor PSMA are receiving increasing atten-
tion [30••, 31, 32]. PSMA is expressed in the prostate,
salivary glands, small intestine and kidneys. However, it
is significantly overexpressed in prostate cancer cells
when compared to the surrounding normal tissue [33,
34]. PSMA is a trans-membrane receptor that internal-
ises bound ligands [35]. It is the internalisation of the
ligand-radionuclide complex that is thought to account
for the high-quality images produced by this technique
[36].
Ga-68 PSMA-targeted diagnostic imaging has many ad-
vantages over traditional PSA testing, not least the ability to
detect anatomically the location of lymph nodemetastases and
distant soft tissue spread. Historically, salvage radiation ther-
apy has been delivered to the prostatic bed without knowledge
of the site of residual disease. This new modality opens the
possibility of salvage surgical or radiation therapy that can be
targeted to the correct location [37]. Two groups have pub-
lished papers in 2015 examining the effectiveness of Ga-68
PSMA imaging for detecting recurrent prostate cancer [30••,
32]. Firstly, Ashfar-Oromich et al. performed a retrospective
analysis in 319 patients who underwent Ga-68 PSMA imag-
ing [30••]. In 292 of these patients, progressive disease was
suspected following prior conventional treatment (e.g., radia-
tion therapy/surgery). Ga-68 identified positive lesions in
50 % of men with a PSA <0.2 ng/ml, and as expected, the
likelihood of a positive lesion correlated to PSA levels. From
this cohort, tissue from 42 patients was isolated for further
histological testing (biopsy/surgery) allowing comparison of
images with gold standard histology. Lesion-based analysis
from these 42 men gave sensitivity, specificity, negative pre-
dictive value and positive predictive values of 76, 100, 91 and
100 %, respectively. Secondly, Dietlein et al. have published a
comparison of two PSMA-labelled radionuclides (Ga-68 and
F-18). In 14 men with biochemical relapse, both PSMA-
labelled isotopes identified positive lesions in 10 pa-
tients [32]. This study was limited by only two patients
having histological confirmation of their positive lesions
but did demonstrate the ability of this technology to
highlight sites of residual disease or metastasis. Further
studies are required with histological verification of pos-
itive lesions before it is adopted into standard practice.
Detecting Skeletal Metastases and Other Distant
Disease
As alluded to earlier, the skeleton is a frequent site ofmetastases in
prostate cancer, and the development of bony disease is an indi-
cator of poor prognosis. For many years, conventional wisdom
has held that the presence of skeletal spread indicates terminal
disease. However, recent interest has emerged in the possibility
of identifying patients with a low burden of metastatic disease
(so-called oligo-metastases), with the aim of offering potentially
curative or disease-controlling therapy [38–42]. Clearly, the
success of this philosophy is likely to depend on the ability to
detect bone disease as early as possible. The involvement of the
skeleton in prostate cancer is an important cause of morbidity and
mortality [43]. Skeletal involvement in prostate cancer is typically
difficult to assess using traditional imaging modalities, such a
plain X-ray and CT, especially in the context of osteoblastic me-
tastases [44]. Scintigraphy has long been a mainstay of assessing
bone disease through the use of radiolabelled Tc99m-methylene
diphosphate (MDP) [45]. MDP uptake by the skeleton is a func-
tion of blood supply, bone turnover and osteoblastic activity.
Although this technique is sensitive at detecting osteogenic activ-
ity, there are limitations. MDP bone scan findings reflect changes
in the bone rather than visualising the tumour. Disease regression
can be difficult to discern due to residual tracer uptake in healing
bone [46]. It is unlikely that conventional scintigraphy possesses
the sensitivity and specificity to detect tiny skeletal deposits of
prostate cancer. To this end, molecular imaging modalities offer
great promise in the early detection of bone metastases.
F18-Sodium Fluoride (NaF) PET Scanning
for Imaging Skeletal Disease
Interest in F18-sodium fluoride (NaF) PETscanning as a tool for
imaging prostate cancer bone metastases has grown in recent
years. Like radiolabelled phosphate analogues, NaF is incorpo-
rated into the hydroxyapatite lattice and collagen matrix of the
skeleton. NaF has a higher affinity to bone than MDP and there-
fore allows earlier imaging time and improved image quality
[47]. Indeed, several studies have indicated that NaF PET per-
forms better than MDP for the assessment of osteoblastic metas-
tases. One notable study compares planar bone scintigraphy,
bone SPECT, NaF PETand NaF-PET/CT in patients with local-
ised, high-risk or metastatic prostate cancer [48]. The sensitivity
and specificity for detecting bone lesions were significantly
higher for NaF PET/CT (100 and 100 %, respectively) than for
planar scintigraphy (70 and 57%), SPECT (92 and 82%) orNaF
PET alone (100 and 62 %). These results favour NaF PET/CT
over conventional scintigraphy for the accurate detection of skel-
etal disease in prostate cancer.
Although NaF PET/CT is generally regarded as superior to
conventional NDP scintigraphy, no prospective studies yet
Curr Urol Rep (2016) 17: 26 Page 3 of 6 26
exist demonstrating any benefit in patient staging or manage-
ment and it is unclear whether NaF will provide more mean-
ingful information. Further clarity is needed to demonstrate a
definitive advantage of NaF over conventional bone scanning
techniques, which are cheaper and more widely available.
FDG-PET to Monitor Treatment Response
in Advanced Disease States
Many prostate tumours possess low glycolytic activity, lead-
ing to the widely held notion that FDG-PET scanning has
limited value in the assessment of prostate cancer. This is
likely to be true in the case of organ-confined disease, where
tumours may display low levels of glycolysis and benign hy-
perplastic or inflammatory pathologies may lead to increased
FDG uptake, leading to false-positive diagnoses [49, 50].
However, FDG-PET may play a role in advanced disease
states, where it has been used to assess response to hormone
and/or chemotherapy in the context of metastatic disease [51].
The Future—Probing Genetic Abnormalities
in Prostate Cancer
Molecular imaging techniques currently used in the clinical
setting to assess prostate cancer largely employ the use of
substrates taken up by metabolising tissues. This approach
risks non-specificity for malignant cells, as well as missing
tumours with low metabolic turnover. To this end, molecular
probes are being developed that specifically target antigens
selectively expressed by prostate cancer cells. In addition,
cancer-specific probes are likely to be of great value as a tool
to delineate the genetic heterogeneity of individual tumours
and thus facilitate targeted, precision therapies [8, 9].
Androgen Receptor (AR) Probes
AR signalling is frequently implicated as a driver of tumour
growth in prostate cancer, and anti-androgen therapy has long
been a mainstay of the treatment of advanced disease.
Invariably, after a period of response to hormone therapy,
prostate tumours progress to a castrate-resistant state. This
complex process is thought to involve either sensitisation or
bypassing of the AR signalling pathway [52].
The distribution of sites where AR is overexpressed can be
imaged using the PET agent [18F]-fluoro-5-alpha-dihydrotes-
tosterone (18F-FDHT) [53, 54]. A recent study evaluated the
associations between morphological CT patterns, glycolytic
activity and AR expression on PETand found that the number
of bone lesions on CT, FDG-PET and FDHT-PET as well as
the intensity of FDHT uptake are significantly associated with
overall survival [55•]. Of particular promise is the potential
use of FDHTas a pharmacodynamic marker of drug targeting.
One study reported that enzalutamide (an AR receptor antag-
onist)-induced FDHT uptake changes in metastatic lesions
could be considered a surrogate marker for response of pros-
tate cancer metastases with AR overexpression to ADT [56].
Conclusions
Prostate cancer is an important cause of morbidity and mor-
tality affecting men worldwide. Herein, we have discussed
several new developments in molecular imaging techniques
that are likely to see increasing adoption over the next decade
and that have good potential to revolutionise the management
of men with prostate cancer.
In the future, molecular imaging techniques are likely to play
a role in the management of prostate cancer at all stages of the
disease, from the use of hyperpolarised MR in organ-confined
disease, to the use of choline or PSMA tracers to detect early
recurrence, right through to the detection of distant disease with
NaF and FDG-PET. Additionally, imaging techniques using
cancer-specific molecular probes (AR probes are an example)
are currently being developed that will provide a non-invasive
method for sub-typing tumours based on genetic or biochemical
signatures. Such advances will help move us into the era of
precision medicine, whereby therapies are tailored according
to the specific characteristics of any given tumour.
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